Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Mycosis fungoides is the most common subtype of cutaneous T-cell lymphoma, in which the expression of cluster of differentiation 30 (CD30)+ subtype can now be treated with the CD30 antibody conjugate brentuximab vedotin. Diagnostic methods are based on immunohistochemical (IHC) staining followed by manual assessment by pathologists, which is always a subjective calculation. QuPath, an open-source software for digital pathology image analysis, satisfies the requirements of objective approaches.
Methods: Ten samples from mycosis fungoides patients with CD30 expression at different stages were stained for CD3 and CD30 by IHC staining, scanned, and quantitative analysis was performed using QuPath (version 2.1). Each slide was independently assessed by 3 board-certified dermatopathologists.
Results: Individual estimates for CD30+/CD3+ cells varied among the individual histopathologists (mean coefficient of variation, 0.46; range, 0-0.78). QuPath analysis showed excellent separation between the positively stained cells for CD3 and CD30 IHC and other cells and tissue structures, although the results correlated strongly with the respective mean estimates of the 3 histopathologists (Pearson-R 0.93).
Conclusions: The results show a high interobserver variability evaluation of IHC markers, although quantitative image analysis offer a significant advantage for comparison. This is not only relevant for clinical routine but also especially critical in therapeutic studies addressing targeted molecules.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/DAD.0000000000002330 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CD63 is a diagnostic marker of prostate cancer and a prognostic marker of biochemical progression following radical prostatectomy.
Histol Histopathol
September 2025
Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Aims: We aimed to analyze CD63, a cell surface protein that has been associated with tumor aggressiveness in several cancers, including breast, colorectal, and lung cancer, as well as melanoma, in prostate cancer.
Methods: CD63 expression was analyzed immunohistochemically in a cohort of primary prostate cancers from 281 patients. The results were correlated with clinico-pathologic parameters, including biochemical recurrence.
Phenotypic and Spatial Characterization of Tumor-Associated Macrophages in Non-Metastatic Seminoma: Association with Local Tumor Progression.
Med Sci (Basel)
August 2025
Department of Digital Oncomorphology, National Medical Research Centre of Radiology, 2nd Botkinsky Pass, 3, 125284 Moscow, Russia.
Seminoma is the most common subtype of testicular germ cell tumors in young men; however, the contribution of tumor-associated macrophages (TAMs) to disease progression remains insufficiently understood. This study aimed to quantitatively and phenotypically characterize CD68 and CD163 TAMs in non-metastatic seminomas (pT1N0M0 and pT2N0M0). : This retrospective, multicenter, cohort, observational, analytical study was conducted from 1 January 2015 to 1 January 2025 at two branches of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation: the A.
View Article and Find Full Text PDFExpression of Alanine-Serine-Cysteine Transporter 2 (ASCT2) and L-type Amino Acid Transporter 1 (LAT1) in Low-Grade and High-Grade Gliomas: An Analysis of Open-Access Immunohistochemical Data.
Cureus
July 2025
Department of Neurosurgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA.
Background: The amino acid transporters alanine-serine-cysteine transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) are the primary transporters of essential amino acids in cancer. ASCT2 and LAT1 are overexpressed in solid tumors and have been associated with poor survival. These transporters may hold prognostic significance and offer potential theranostic utility in the treatment of glioma.
View Article and Find Full Text PDFThe immunologic landscape of HRAS-mutant head and neck squamous-cell carcinoma.
ESMO Open
August 2025
Oncology Unit, 2nd Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Haidari, Greece. Electronic address:
Background: HRAS mutations define a distinct biologic subset of head and neck squamous-cell carcinoma (HNSCC). There are limited data regarding HRAS-mutant (mut) tumors' sensitivity to immunotherapy. We sought to evaluate the mutational landscape and transcriptional profile, as well as analyze the tumor microenvironment (TME) of HRAS-mut tumors to provide the conceptual framework for combinatorial treatment approaches.
View Article and Find Full Text PDFMiroSCOPE: An AI-driven digital pathology platform for annotating functional tissue units.
bioRxiv
July 2025
Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR, USA.
Cancer tissue analysis in digital pathology is typically conducted across different spatial scales, ranging from high-resolution cell-level modeling to lower-resolution tile-based assessments. However, these perspectives often overlook the structural organization of functional tissue units (FTUs), the small, repeating structures which are crucial to tissue function and key factors during pathological assessment. The incorporation of FTU information is hindered by the need for detailed manual annotations, which are costly and time-consuming to obtain.
View Article and Find Full Text PDF